Selected data models

You must log in to select data models for download or further analysis.

36 Search results.
Relevance Rating New first Old first

AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients NCT00180102 - nach 2. Induktionstherapie

- 27/09/2021 - 25 forms, 8 itemgroups, 84 items, 1 language
Itemgroups: Shipping of Material, Blood count, Clinical Chemistry, Bone Marrow Morphology, Treatment outcome evaluation, Risk group, Planned first post remission treatment, Planned first post remission treatment
NCT00180102 AML2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia. Phase 4 Study Type:Interventional Study Design:Allocation: Randomized Intervention Model:Factorial Assignment Masking:None (Open Label) Primary Purpose:Treatment Medical Department I, University Hospital Carl Gustav Carus Dresden, Germany, 01307 Sponsors and Collaborators Technische Universität Dresden Principal Investigator:Gerhard Ehninger, MD University Hospital Carl Gustav Carus Dresden

nach 1. Induktionstherapie

8 itemgroups 79 items

Ersterhebung

7 itemgroups 38 items

2. Induktionstherapie - Unerwünschte Ereignisse CTC 3.0 -

2 itemgroups 13 items

Diagnostik vor Therapiebeginn

4 itemgroups 67 items

Chimerism Studies NHLBI - Lab Chimerism Studies

- 20/09/2021 - 1 form, 10 itemgroups, 52 items, 1 language
Itemgroups: Registry Use Only, Identification Data, HSCT Type, Product Type, Follow Up Visit, Vital Status, Chimerism Studies, Single Donor, Multiple Donors, Author Information
2451 Revision 1 - Chimerism Studies Lab - 2451 Revision 1 - Chimerism Studies - 3160257v1.0 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9542E77F-E1D1-5D08-E040-BB89AD435C29

Follow-Up for Greater Than Two Years Post-HSCT Data

- 20/09/2021 - 1 form, 14 itemgroups, 255 items, 1 language
Itemgroups: Registry Use Only, Identification Data, HSCT Type, Product Type, Follow Up Visit, Vital Status, Functional Status, Acute GVHD, Chronic GVHD, New Malignancy, Other Organ Impairment, Subsequent HSCT, Donor Cellular Infusion, Author Information
2300 Revision 2 - Yearly Follow-Up for Greater Than Two Years Post-HSCT Data Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=849DFDB6-D6C2-FF34-E040-BB89AD431324

Infectious Disease Markers NHLBI - Lab Infectious Disease Markers ISO Date Format Version 1 2004

- 20/09/2021 - 1 form, 14 itemgroups, 48 items, 1 language
Itemgroups: Registry Use Only, Identification Data, HSCT Type , Product Type, Source Information, Hepatitis B Virus, Hepatitis C Virus, Human T-Lymphotropic Virus, Human Immunodeficiency Virus, Syphilis, Cytomegalovirus, West Nile Virus, Infectious Disease Marker, Author Information
Infectious Disease Markers Uses The ISO Date Format Version 1 Lab - 2004 - Infectious Disease Markers ISO Date Format Version 1 - 2884169v1.0 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6A861230-7A94-FE96-E040-BB89AD434611

2005 Confirmation of HLA typing - NHLBI

- 20/09/2021 - 1 form, 12 itemgroups, 81 items, 1 language
Itemgroups: Registry Use Only, Identification Data, HSCT, Product Type, HLA Typing Source, HLA Typing by DNA Technology, HLA Typing by DNA Technology: Class I , HLA Typing by DNA Technology: Class I , HLA Typing by DNA Technology: Class II (Optional) , Antigens Defined by Serologic Typing , Optional Antigen Reporting: Antigens Defined by Serologic Typing , Author Information
Confirmation of HLA Typing Uses The ISO Date Format Version 1 This form must be completed for all non-NMDP allogeneic or syngeneic donors or recipients, or non-NMDP cord blood units. If the donor, recipient, or cord blood unit was secured through the NMDP, then report HLA typing on the appropriate NMDP forms. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6AA94BD8-0ED4-61A3-E040-BB89AD434BE8

HSCT recipients - Cause of death

- 20/09/2021 - 1 form, 9 itemgroups, 24 items, 1 language
Itemgroups: Registry Use Only, Identification Data, HSCT Type , Product Type, Death Date, Autopsy report, Primary Cause of Death, Secondary Cause of Death, Author Information
To define the primary and contributing causes of death for HSCT recipients reported as dead on follow up forms 2900 - RECIPIENT DEATH DATA Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6B9DD88E-9E08-08A7-E040-BB89AD430716

Eligibility Acute Leukemia NCT01020175

- 20/09/2021 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT01020175

Eligibility NCT00682396 Myelodysplastic Syndrome - Eligibility

- 20/09/2021 - 1 form, 2 itemgroups, 28 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00682396

Patient identification Stem-Cell Transplantation CASLAMB NCT00148148

- 17/09/2021 - 1 form, 2 itemgroups, 17 items, 2 languages
Itemgroups: Patient demographics, Information about primary diseases
A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation NCT00148148

Study completion-Lab Stem-Cell Transplantation CASLAMB NCT00148148

- 17/09/2021 - 1 form, 11 itemgroups, 46 items, 2 languages
Itemgroups: Documentation Date, Electrolytes, Metabolism, liver, Pancreas, Kidney, Infection, Coagulation (optional), Hematology, Hematology (optional, absolute values), Urine screening status
A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation NCT00148148

Eligibility NCT00148148 # Stem-Cell Transplantation - Eligibility

- 13/04/2021 - 1 form, 3 itemgroups, 51 items, 2 languages
Itemgroups: Inclusion criteria, Exclusion criteria, Medical Concepts
The study compares the safety, efficacy and pharmacokinetics of caspofungin, liposomal amphotericin B or the combination of both in the antifungal treatment of adult patients after allogeneic haematopoietic stem-cell transplantation with granulocytopenia and persistent i.g. recurrent fever under adequate antibacterial therapy.

Eligibility Stem Cell Transplantation NCT00813124

- 04/11/2018 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML); ODM derived from: https://clinicaltrials.gov/show/NCT00813124

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial